scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

Company Overview - scPharmaceuticals, Inc. (SCPH) shares increased by 8.8% to close at $5.84, with trading volume significantly higher than usual, reflecting a 35.3% gain over the past four weeks [1][2] Product Performance - The rise in stock price is linked to positive investor sentiment regarding the initial sales of Furoscix (furosemide injection), which treats edema in adult patients with chronic heart failure or chronic kidney disease [2] Financial Expectations - The company is projected to report a quarterly loss of $0.30 per share, marking a year-over-year increase of 31.8%. Expected revenues are $16.4 million, representing a 103.7% increase from the same quarter last year [3] - The consensus EPS estimate for scPharmaceuticals has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [4] Industry Context - scPharmaceuticals is categorized under the Zacks Medical - Biomedical and Genetics industry, where Celldex Therapeutics (CLDX) is another player, having closed 2.7% lower at $23.22, with an 11.2% return over the past month [5] - Celldex's consensus EPS estimate has also remained unchanged at -$0.86, reflecting a year-over-year change of -59.3% [6]